Clinical Trials for Non-Small Cell Lung Cancer

PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with oligometastatic breast cancer (all subtypes) or non-small cell lung cancer (1-5 measurable metastases) who are randomized to receive either standard systemic therapy or standard systemic therapy plus stereotactic body radiotherapy (SBRT) to all metastatic sites. Eligible patients may have newly diagnosed or stable metastatic disease and must have lesions suitable for SBRT or local therapy.

ClinicalTrials.gov ID: NCT03808337

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced non-squamous NSCLC and ECOG 0-1 whose disease progressed after maintenance pemetrexed and/or pembrolizumab, this trial investigates carboplatin, weekly paclitaxel, and ramucirumab (a VEGFR-2 inhibitor monoclonal antibody), excluding patients with targetable driver mutations or untreated brain metastases.

ClinicalTrials.gov ID: NCT04332367

LUNG-IST-127: a Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab (CP) for Patients with Metastatic SqNSCLC with Disease Control Following Induction Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Eligible patients are adults with metastatic squamous NSCLC (stage IV, ECOG 0-2) who achieved disease control after four cycles of first-line pembrolizumab, carboplatin, and (nab-)paclitaxel; these patients receive maintenance cabozantinib (a multi-kinase inhibitor targeting MET/VEGFR and others) plus pembrolizumab.

ClinicalTrials.gov ID: NCT05613413

Phase II Trial of Lung Chemoemobolization

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, unablatable non-small cell lung cancer or lung metastases progressing on or intolerant to systemic therapy receive transarterial chemoembolization (TACE) with intra-arterial mitomycin (alkylating cytotoxic agent), lipiodol (contrast/drug carrier), and embospheres (arterial embolic microspheres). This trial targets patients not eligible for surgery, ablation, or radiation, assessing local disease control using a locoregional approach.

ClinicalTrials.gov ID: NCT05672108

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients with Extra-Cranial Soft Tissue Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors and at least two extracranial soft tissue metastases (one ≥4 cm) requiring palliative radiation, comparing lattice radiation therapy (LRT)—a spatially fractionated radiotherapy technique that may enhance immune effects—to standard SBRT, with each patient receiving both treatments at different sites.

ClinicalTrials.gov ID: NCT05837767

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic NSCLC, especially those with EGFR mutations (exon 19 deletion, exon 21 L858R, or exon 20 insertion) at various lines of therapy, to evaluate subcutaneous amivantamab—a bispecific EGFR/MET antibody—given alone or in combination with lazertinib, chemotherapy, or following IV amivantamab. Key exclusions include symptomatic brain metastases, significant cardiovascular disease, or history of ILD.

ClinicalTrials.gov ID: NCT05498428

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This study enrolls adults with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have not received prior therapy for advanced disease, testing the KRAS G12C inhibitor adagrasib (MRTX849), alone or combined with pembrolizumab, versus pembrolizumab alone (phase 3 for PD-L1 TPS ≥50%).

ClinicalTrials.gov ID: NCT04613596

A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic NSCLC (ECOG 0-2, no EGFR/ALK mutations, predominantly PD-L1 ≥50%), who have detectable ctDNA after initial pembrolizumab, and randomizes those with persistent ctDNA at 6 weeks to either continued pembrolizumab monotherapy (a PD-1 inhibitor) or pembrolizumab combined with platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT04093167

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or recurrent NSCLC harboring EGFR exon 20 insertion mutations who have received at least one prior therapy, treating them with osimertinib 160 mg daily, an investigational third-generation irreversible EGFR tyrosine kinase inhibitor, to assess efficacy and safety in this mutation subset. Patients must have good performance status and measurable disease, with key exclusions including prior osimertinib, recent immunotherapy, untreated CNS metastases, and significant comorbidities.

ClinicalTrials.gov ID: NCT03191149